Electronic Supplementary Information

## An NIR-Sensitive Layered Supramolecular Nanovehicle for Combined Dual-Modal Imaging and Synergistic Therapy

Shanyue Guan,<sup>†a</sup> Yangziwan Weng,<sup>†a</sup> Mengnan Li,<sup>c</sup> Ruizheng Liang,<sup>\*b</sup> Chenghua Sun,<sup>\*a</sup> Xiaozhong Qu<sup>\*c</sup> and Shuyun Zhou<sup>a</sup>

- a. Key Laboratory of Photochemical Conversion and Optoelectronic Materials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Beijing, 100190, P. R. China.
- b. State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, P. R. China.
- c. College of Materials Science and Opto-Electronic Technology, University of Chinese Academy of Sciences, Beijing 100190, P. R. China.
- \* Corresponding authors.

Email: quxz@iccas.ac.cn (X. Q.); sunchenghua@mail.ipc.ac.cn (S.Z.);

liangruizheng2000@163.com (R.L.)

Sample	Chemical Composition	$\frac{Mg^{2+}}{/Al^{3+}}$
Gd-LDH	Mg0.581Al0.366Gd0.053(OH)2	1.59
DOX/Gd-LDH	$Mg_{0.602}Al_{0.356}Gd_{0.032}(OH)_2 DOX_{0.00905}$	1.69
ICG/Gd-LDH	Mg0.674Al0.312Gd0.029(OH)2ICG0.024SDS0.0127	2.16
ICG-DOX/Gd- LDH	Mg0.641Al0.312Gd0.025(OH)2 ICG0.0192DOX0.0153 SDS0.0104	2.05

Table S1. Chemical compositions of various composites.



Figure S1. FTIR spectra of SDS and ICG-DOX/Gd-LDH, respectively.



Figure S2. HRTEM images and lattice of the ICG-DOX/Gd-LDH.



**Figure S3.** Particle size distribution of ICG-DOX/Gd-LDH determined by dynamic lighting scatting analyzer (DLS).



**Figure S4.** Stability test of ICG, ICG/Gd-LDH and ICG-DOX/Gd-LDH under the room temperature for 15 days.



Figure S5. Zeta potential of ICG/Gd-LDH and ICG-DOX/Gd-LDH, respectively.



Figure S6. Zeta potential of ICG-DOX/Gd-LDH at various pH values.



**Figure S7.** Cumulative DOX release from ICG-DOX/Gd-LDH under a simulant physiological condition (PBS buffer solution, pH=7.4) with and without NIR irradiation.



**Figure S8.** The confocal imaging photographs of ICG-DOX/Gd-LDH incubated with Hela cells for 3h with and without NIR irradiation.



**Figure S9.** Fluorescence intensity of Gd-LDH, and ICG-DOX/Gd-LDH under dark and irradiation.



**Figure S10.** Fluorescence imaging of KB cells and HepG-2 cells incubated with ICG-DOX/Gd-LDHs, respectively.



**Figure S11.** Confocal fluorescence images of Hela cells incubated ICG-DOX/Gd-LDH for 3h, 6h and 12 h, respectively.



**Figure S12.** ROS images inside Hela cells with the incubation with ICG and ICG-DOX/Gd-LDH after the NIR irradiation for 10 mins.



**Figure S13.** Time series of ROS images inside Hela cells after treatment with various samples under NIR irradiation therapy.



**Figure S14.** Time series of changes in the related ROS levels after treatment with various samples under NIR irradiation therapy.



**Figure S15.** (a) Viability of Gd-LDH incubated with Hela cell for 24 h and 48 h. (b) The viability of ICG/Gd-LDH (b) DOX/Gd-LDH (c) and ICG-DOX/Gd-LDH under dark and irradiation. The laser group were irradiated at 808 nm with the power of 1 W/ cm<sup>2</sup>.



**Figure S16.** H&E-stained organs isolated from tumor bearing mice treated by ICG-DOX/Gd-LDH formulation.



Figure S17. UV-vis diffuse reflectance spectra of Gd-LDH.